BioPharmSignal logoBioPharmSignal

Biotech News

Erasca to Present at the Jefferies Global Healthcare Conference

Erasca (ERAS)ErascaConference / presentation

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies

Open original release

Related news

ERASErasca2026-05-06 12:00 EST

Erasca to Present at the Bank of America Securities Health Care Conference

ERASErasca2026-05-11 11:00 EST

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

IDYAIDEAYA Biosciences2026-05-26 10:00 EST

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KURAKura Oncology2026-05-06 11:30 EST

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

View all latest news

Erasca

Erasca is an oncology company focused on precision medicine and targeted cancer therapies. Its pipeline is built to address genetically defined tumor biology.

Recent company news

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

ERASErasca2026-05-11 20:01 EST

Erasca Reports First Quarter 2026 Business Updates and Financial Results

ERASErasca2026-05-11 11:00 EST

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

ERASErasca2026-05-06 12:00 EST

Erasca to Present at the Bank of America Securities Health Care Conference

ERASErasca2026-04-27 20:01 EST

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Stock data

Close
18.87 USD
Market cap
4.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States